Related Experiment Video
Updated: May 20, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
[Local oestrogen therapy and recurrence risk in women in endocrine adjuvant breast cancer therapy]
Lisette Hvid Hovgaard1, Julie H Tharin2, Signe Borgquist3,4
1Afdeling for Gynækologi, Fertilitet og Fødsler, Københavns Universitetshospital - Rigshospitalet.
Abstract:
Women treated for breast cancer often experience vulvovaginal atrophy (VVA). Vaginal oestrogen therapy (VET) can alleviate symptoms, but the impact on the risk of breast cancer recurrence is unclear. Based on a review of published studies of VET in patients with previous breast cancer, tamoxifen (TMX) users had no increase in breast cancer recurrence. In contrast, one study suggests a higher recurrence risk among aromatase inhibitor (AI) users compared to non-users. In conclusion, this review finds that VET can safely be used as VVA treatment in TMX users, whereas it should be used cautiously in AI users.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Related Concept Videos
Oogenesis
Disorders of the Female Reproductive System
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Treatment Resistant Cancers